

Current Report

Current Report according	- Regulation no.5/2018
Date of the report:	- 25.09.2018
Name of the issuer	- <i>ZENTIVA S.A.</i>
Main seat:	- <i>Bd. Theodor Pallady nr.50, Bucuresti</i>
Tel. /Fax no.:	- 021-3047200 /021-345.40.04
Unique Code:	- 336206
Registration No.	- J40/363/1991
Shared capital	- 41.696.115 RON
Capital market	- <i>Bucharest Stock Exchange</i>

Significant events to be reported:

With regard to the contracts referred to in the Current Report dated on 06.09.2018, Zentiva SA (“the Company”) informs:

1. On 25.09.2018, Zentiva SA has concluded with the affiliated company, Sanofi (France), an amendment to the contract having as object transfer to Sanofi of the ownership over pharmaceutical products in the range of non-prescription medicinal products held by the Company, respectively of the assets belonging to these pharmaceuticals (trademarks, domains, pharmaceutical dossiers and associated know-how) as well as the transfer of the ownership over pharmaceutical dossiers and associated know-how related to medicines in the Generic medicines area held by the Company.

The amendment regards the change of the list of the pharmaceutical products which are transferred, respectively of the assets belonging to these pharmaceuticals products, as well as the change of the value of the initial contract. After the amendment, the new value of the contract is 53.485.466 Euro.

As per the available internal accounting data, at 25.09.2018 there are no mutual receivables of the parties.

2. On 25.09.2018, Zentiva SA has concluded with the affiliated company, Sanofi (France), an amendment to the license agreement granting by Sanofi to the Company a license over pharmaceutical dossiers related to medicines in the Generic medicines area.

The amendment regards the change of the list of the pharmaceutical products subject to the license, as well as the change of the value of the initial contract. After the amendment, the new value of the contract is 607.875 Euro.

As per the available internal accounting data, at 25.09.2018 there are no mutual receivables of the parties.

3. On 25.09.2018, Zentiva SA has concluded with the affiliated company, Sanofi (France), an amendment to the license agreement granting by the Company to Sanofi a license over pharmaceutical dossiers related to medicines in the Generic medicines area held by the Company.

The amendment regards the change of the list of the pharmaceutical products subject to the license, as well as the change of the value of the initial contract. After the amendment, the new value of the contract is 317.738 Euro.

As per the available internal accounting data, at 25.09.2018 there are no mutual receivables of the parties.

Simona Cocos
General Manager